Healthcare Industry News: OXiGENE
News Release - December 12, 2006
Donald S. Masters, Ph.D. Named New President and CEO of Triton BioSystems, Inc.
CHELMSFORD, Mass.--(HSMN NewsFeed)--Triton BioSystems, Inc. (TBS), announced today it has hired Dr. Donald S. Masters as its President and CEO effective immediately. An early stage biotechnology company, TBS is developing promising targeted nanotherapeutic products for the treatment of cancer. Dr. Masters brings over 27 years experience in the biotechnology field, most recently as CEO of Esperance Pharmaceuticals of Baton Rouge, LA.Dr. Masters will be responsible for all strategic direction of the company, including the completion of pre-clinical testing, expanding its investor base, initiating human clinical trials and forming global partnerships. "We are very excited to have Donald lead the TBS team," stated Mr. Rudy Mazzocchi, TBS Chairman of the Board. "His wealth of experience and talent in successfully leading biotechnology companies will be crucial to the company's continued success."
Prior to joining TBS, Dr. Masters held the position of President and CEO at several biotechnology start-up companies including Esperance Pharmaceuticals, C3 Scientific Corporation, Bion, Inc. and OXiGENE, Inc. He was also Director of Biomedical Applications for TASC, Inc. which led to being a founder of a telemedicine company using TASC technology. Dr. Masters began his career as a member of the Harvard-Monsanto Project, the groundbreaking multimillion-dollar university/industry research collaboration. He then went on to become the fifth employee at Genzyme, creating their successful Research Biologicals business unit which was eventually sold for $67 million. Dr. Masters graduated from The Johns Hopkins University with a degree in Biophysics, received his Ph.D. in Biochemistry and Immunology from Cornell University Medical College and was a Post-doctoral Fellow at Harvard Medical School.
"I'm excited to be joining TBS as its President and CEO," stated Dr. Masters. "As a scientist and entrepreneur, I believe this technology will provide a much needed solution to a serious problem in treating cancer." Dr. Masters also noted that, "its potential to target and kill cancer cells without invasive surgery or the toxicity of chemotherapies will provide a promising treatment for cancer patients, and specifically patients with metastasized breast cancer."
Dr. Masters succeeds Dr. Samuel Straface, founding CEO of Triton BioSystems who led the Company for 4 years, building the organization, its partnerships, intellectual property and product portfolios. Dr. Straface continues to be an advisor to the company and Dr. Masters during the transition.
The technology employs patented nano-sized magnetic particles attached to antibodies to seek-out cancer cells within the body. Once the particles find and attach themselves to a cancer cell, a magnetic field is applied causing the particle to heat up and destroy the cell membrane. This provides the ability to kill tumors that are too small in the body to find and diagnose. Alternatively, the magnetic particles (without antibodies attached) can be injected directly into larger tumors and activated by the magnetic field causing the tumor to die by hyperthermia.
About Triton BioSystems
Triton BioSystems, Inc. is a private-equity backed, development-stage biotechnology company located in Chelmsford, Massachusetts and is focused on the discovery and development of targeted nanotherapeutics that use localized hyperthermia to treat cancer. For more information about Triton BioSystems, please visit http://www.TritonBioSystems.com/.
Source: Triton BioSystems
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
